See Why We Have Quantum BioPharma (NASDAQ: QNTM) On Our Radar Early This Morning

*Sponsored by Quantum BioPharma Ltd. Market Crux Exclusive: Quantum BioPharma (NASDAQ: QNTM)  Captures the Spotlight Early This Morning! And Here’s Why… Analyst Confidence: Singular Research’s $12.80 price target reflect over 300% upside from this morning’s opening at around $3.18. Under the Radar: Quantum BioPharma (NASDAQ: QNTM)’s market cap under $6.5 Mn highlights how it remains largely unnoticed despite its recent progress. Tiny Float: With fewer than 1.6 Mn shares available, Quantum BioPharma Ltd. (NASDAQ: QNTM)’s small float could lead to significant swings if demand begins to shift. December 20, 2024 Dear Reader, Reshaping the future of healthcare requires precision, bold innovation, and the ability to deliver results where it matters most.  A significant breakthrough in the fight against multiple sclerosis has just cleared a critical milestone, signaling major progress ahead.  Behind this development is a company steadily making its mark in neurological treatments.  Quantum BioPharma (NASDAQ: QNTM) has received safety committee approval to advance its Phase 1 trial for Lucid-21-302 (Lucid-MS), greenlighting dosing for the second cohort. This approval follows a rigorous review of safety and pharmacokinetic data from the first cohort, reflecting the company’s dedication to scientific rigor and patient safety. Dr. Andrzej Chruscinski, Vice-President of Scientific and Clinical Affairs, emphasized the team’s excitement as preparations to dose the next group are now underway.  This is not just a routine checkpoint—it’s a clear sign that Quantum BioPharma (NASDAQ: QNTM) is building meaningful momentum toward transforming the treatment landscape for multiple sclerosis and beyond. Keep reading to see why Quantum BioPharma Ltd. (NASDAQ: QNTM) is topping our watchlist this morning.  In a bold move, Quantum BioPharma Ltd. (NASDAQ: QNTM) has launched a $700M lawsuit, targeting well-known institutions for alleged 'spoofing' practices. This development could be the precursor to major breakthroughs ahead. Quantum BioPharma (NASDAQ: QNTM), with its market cap currently under $6.5M, may have been flying under Wall Street's radar—until now. Quantum BioPharma (NASDAQ: QNTM) dropped to $3.15 yesterday, entering what some consider “Severely Oversold” territory.  The Relative Strength Index (RSI), a trusted momentum indicator, is often the benchmark for identifying such conditions.  The RSI measures the speed and magnitude of price changes on a scale from 0 to 100, with readings below 30 signaling oversold conditions and readings above 70 indicating overbought levels.  As of 12/19, Quantum BioPharma (NASDAQ: QNTM)’s RSI numbers tell the story clearly.  The 9-day RSI sits at a low 19.80%, well below the oversold threshold. The 14-day RSI reads 27.97%, also in oversold territory, while the 20-day RSI at 34.30% remains close enough to suggest the potential for a reversal. What makes this even more compelling is the company’s exceptionally small float—fewer than 1.6 Mn shares, according to FinViz. When supply is this limited, even modest changes in demand can lead to significant volatility.  Adding to the excitement, Singular Research recently reiterated its bullish stance on Quantum BioPharma (NASDAQ: QNTM), setting a target of $12.80 per share. From yesterday’s opening of $3.18, this suggests a potential upside of over 300%, signaling strong confidence in the company’s future. With its small float, RSI trending in what appears to be oversold territory, analyst coverage, and potential for growth, Quantum BioPharma (NASDAQ: QNTM) checks all the boxes we look for in a profile. Taking a Look at Quantum BioPharma (NASDAQ: QNTM) Quantum BioPharma (NASDAQ: QNTM) is leading the way in biopharmaceutical innovation, focusing on groundbreaking treatments for neurodegenerative and metabolic disorders, along with solutions for al-co-hol misuse.  With a diverse portfolio of candidates at various stages of development, the company is committed to addressing some of the most complex medical challenges. Through its subsidiary, Lucid Ps-ych-eceu-ticals Inc., Quantum BioPharma (NASDAQ: QNTM) is making significant progress with its lead compound, Lucid-MS, which plays a key role in the company’s mission to combat serious disorders affecting many people worldwide. One of their most promising initiatives, Lucid-MS, is a patented chemical entity designed to target multiple sclerosis (MS), a chronic, often disabling disease that affects approximately 2.8Mn people globally.  The multiple sclerosis therapeutic market is projected to grow from $21B in 2024 to $38B by 2032, underscoring the increasing need for effective treatments for this debilitating condition. Lucid-MS is designed to address the underlying cause of MS by preventing and reversing myelin degradation.  Myelin is a protective sheath that covers nerve fibers, and its degradation is a key mechanism in the development of multiple sclerosis.  Preclinical models have shown that Lucid-MS is a neuroprotective compound with the potential to halt or reverse myelin damage, offering hope for improved outcomes for those affected by MS and other neurodegenerative conditions. Revolutionizing Al-co-hol Detoxification Quantum BioPharma (NASDAQ: QNTM) is making notable advancements in the al-co-hol detox space with the development of unbuzzd™, a product designed to boost mental alertness and aid detoxification after al-co-hol consumption.  This innovative solution addresses a pressing public health issue, blending scientific research with practical applications in al-co-hol metabolism. In 2023, unbuzzd™ was introduced to the market by Celly Nutrition Corp., a spin-off of Quantum BioPharma (NASDAQ: QNTM), with the company retaining a 25.71% stake.  The product, created by industry leaders from Coca-Cola and Celsius Holdings, has already secured a major distribution agreement with FUSION Distribution Group, bringing unbuzzd™ to Puerto Rico, the Caribbean, and parts of Central and South America.  Currently available as Ready-to-Mix powder sticks on Amazon, unbuzzd™ will soon be available in Ready-to-Drink cans. With distribution set to expand through major retailers like Walmart and Costco, unbuzzd™ is positioned to transform the al-co-hol detox market by providing a much-needed solution for consumers seeking to metabolize al-co-hol faster and enhance mental clarity. Endorsed by Kevin Harrington, one of the original "Sharks" on Shark Tank and a seasoned entrepreneur in health and wellness, unbuzzd™ has attracted significant attention for its potential impact.  Harrington, renowned for identifying groundbreaking products, believes unbuzzd™ could change how society approaches al-co-hol consumption and detoxification. Harrington remarked on the product’s potential, noting that unbuzzd™ could offer a vital solution for those who consume al-co-hol, with the ability to reduce its harmful effects and improve lives on a large scale. In his testimonial, Harrington recalled a real-life example, saying, “I saw someone intoxicated take this product. Within minutes, their demeanor shifted, and their blood al-co-hol levels dropped. unbuzzd™ has the power to revolutionize the al-co-hol detox space.” With a strong focus on advancing solutions for multiple sclerosis, neurodegenerative diseases, and al-co-hol misuse, Quantum BioPharma (NASDAQ: QNTM) continues to solidify its role in biopharmaceutical innovation. As the company expands its portfolio of transformative treatments, its ongoing progress in these areas warrants close attention. 7 Reasons Why Quantum BioPharma (NASDAQ: QNTM) is #1 On Our Watchlist This Morning… 1. Analyst Confidence: Singular Research’s $12.80 target reflects over 300% upside potential from yesterday’s $3.18 opening. 2. Overlooked: Quantum BioPharma (NASDAQ: QNTM)’s market cap under $6.5 Mn highlights how it remains largely unnoticed despite its recent progress. 3. Limited Float: With fewer than 1.6Mn shares available, Quantum BioPharma (NASDAQ: QNTM)’s small public float could lead to the potential for significant swings if demand begins to shift.  4. Technical Signals: RSI levels suggest Quantum BioPharma (NASDAQ: QNTM) is nearing oversold territory, often associated with potential trend reversals. 5. Clinical Progress: Lucid-21-302 (Lucid-MS) has received ethics approval to advance to the next stage of its Phase 1 trial. 6. Growing Market Demand: The market for multiple sclerosis treatments is expected to nearly double, from $21B in 2024 to $38B by 2032, creating space for new entrants like Lucid-MS. 7. unbuzzd™ Scaling Fast: With endorsements and global distribution, unbuzzd™ is expanding its reach and preparing for major retail availability. Final Thoughts Quantum BioPharma (NASDAQ: QNTM) is showing all the signs of a company with significant untapped potential. With a market cap under $6.5Mn, it’s surprising how overlooked this player remains despite its progress. Singular Research’s $12.80 target points to over 300% upside potential from yesterday’s opening, backed by technical signals suggesting a potential reversal and a float of fewer than 1.6 Mn shares, could lead to the potential for significant swings if demand begins to shift.  The company’s clinical advancements with Lucid-21-302 (Lucid-MS) position it to enter a multiple sclerosis treatment market that is set to nearly double over the next decade.  Meanwhile, unbuzzd™ continues to gain momentum, scaling rapidly with endorsements and global distribution paving the way for major retail expansion.  Quantum BioPharma (NASDAQ: QNTM) is more than just an under-the-radar player—it’s a company quietly building toward something substantial, making it one to watch closely in the days ahead. This is no time for games. Quantum BioPharma (NASDAQ: QNTM) is capturing our attention this morning. Consider adding Quantum BioPharma (NASDAQ: QNTM) to your radar. Don’t wait for the opening bell to ring when you can start your research early. We have all eyes on (QNTM) right now. I’ll be following up with you shortly. Watch for my next update on (QNTM). Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired by TD Media LLC for a period beginning on 12/19/2024 and ending on 12/20/2024 to publicly disseminate information about (QNTM:US) via digital communications. Under this agreement, Headline Media LLC has been paid seven thousand five hundred USD (“Funds”) to disseminate information about (QNTM:US) via digital communications. These Funds were part of the funds that TD Media LLC received from Quantum BioPharma Ltd., the issuer. To date, including under the previously described agreement, Headline Media LLC has been paid thirty-two thousand five hundred USD (“Funds”) for (QNTM:US). Neither Headline Media LLC, TD Media LLC or their members own shares of (QNTM:US). Please see important disclosure information here: https://marketcrux.com/disclosure/qntm/

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice